MAKING THE CONNECTION: TRIGLYCERIDES, RESIDUAL CARDIOVASCULAR RISK AND PANCREATITIS
This slide deck summarises the latest evidence supporting an association between hypertriglyceridaemia and atherosclerotic cardiovascular disease even when LDL-cholesterol is well controlled, and considers the potential of triglycerides and triglyceride-rich lipoprotein remnants as targets for future therapies to reduce residual cardiovascular risk and acute pancreatitis.
Icosapent ethyl is a highly purified ethyl ester of the omega-3 fatty acid, eicosapentaenoic acid, and is indicated for reducing cardiovascular events in adults at high cardiovascular risk with elevated triglycerides. This slide deck summarises completed clinical trials, including the landmark REDUCE-IT trial, and ongoing studies.
Evinacumab is an ANGPTL3 inhibitor indicated as an adjunct to diet and other LDL-C lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia. This slide deck summarises current clinical trial data and key ongoing studies.
Olezarsen (formerly AKCEA-APOCIII-LRx) is an investigational antisense medicine designed to reduce the production of apoC-III. This slide deck summarises results of completed early phase studies as well as the aims and objectives of the Phase 3 BALANCE study in patients with familial chylomicronaemia syndrome.
Pemafibrate is a selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) approved for the management of dyslipidaemia and hypertriglyceridaemia. This slide deck summarises results of a series of clinical trials, including PROVIDE in patients with type 2 diabetes and elevated triglycerides, and ongoing studies.
Volanesorsen is an antisense oligonucleotide that inhibits the production of apoCIII and is currently indicated as an adjunct to diet in adult patients with genetically confirmed familial chylomicronaemia syndrome and at high risk for pancreatitis, in whom response to diet and triglyceride-lowering therapy has been inadequate. This slide deck summarises results of the completed COMPASS and APPROACH studies.
(Pfizer-led clinical development programme discontinued in January 2022).
Vupanorsen is a second-generation N-acetyl galactosamine (GalNAc)-modified antisense oligonucleotide that targets hepatic ANGPTL3 mRNA. The Pfizer-led clinical development programme was discontinued in January 2022 following initial data from the TRANSLATE-TIMI 70 study showing more frequent liver enzyme elevations and dose-related increases in hepatic fat fraction compared to placebo. This slide deck summarises clinical trials to date.